Reaction

Tumour Haemorrhage reporting signals

Last recalculated 2026-09-14T18:28:35.993900+00:00 · 2,814 reports · 77 co-occurring drugs

As of the last recalculation, Tumour Haemorrhage appears in 2,814 FAERS reports alongside 77 co-occurring drug terms. The strongest observed disproportionality signal is LENVATINIB (PRR 43.3).

Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.

Drug	Co-reports	PRR	ROR
Lenvatinib	180	43.3	43.5
Atezolizumab	182	37.0	37.2
Bevacizumab	349	23.7	23.7
Sorafenib	51	18.5	18.5
Temozolomide	48	17.1	17.2
Cetuximab	60	14.5	14.5
Imatinib Mesylate	49	13.2	13.2
Regorafenib	20	12.8	12.8
Sunitinib Malate	65	12.5	12.5
Vemurafenib	20	12.4	12.4
Nivolumab	151	12.2	12.2
Vismodegib	14	11.7	11.7
Ipilimumab	64	11.2	11.2
Trifluridine And Tipiracil	16	11.1	11.1
Tranexamic Acid	13	10.9	10.9
Cisplatin	110	10.8	10.8
Paclitaxel (Aibumin-Bound)	114	10.6	10.7
Pembrolizumab	144	10.6	10.6
Ado-Trastuzumab Emtansine	12	10.6	10.6
Paclitaxel	133	10.4	10.4
Dabrafenib	29	10.3	10.3
Ifosfamide	29	10.1	10.1
Pazopanib Hydrochloride	34	9.4	9.4
Trametinib	30	9.3	9.3
Irinotecan Hydrochloride	16	9.3	9.3
Fluorouracil Cream, 0.5%	84	8.4	8.4
Fluorouracil	85	8.3	8.4
Febuxostat Tablets 40 Mg	11	8.0	8.0
Febuxostat Tablets 80 Mg	11	8.0	8.0
Cabozantinib	50	7.8	7.8
Axitinib	20	7.6	7.6
Fam-Trastuzumab Deruxtecan-Nxki	10	7.4	7.4
Durvalumab	20	7.3	7.3
Oxaliplatin	71	7.2	7.2
Fexofenadine Hcl	8	6.4	6.4
Granisetron Hydrochloride	9	6.4	6.4
Mesna Injection	7	6.3	6.3
Mesna	7	6.2	6.2
Apixaban	54	6.1	6.1
Rivaroxaban	156	5.8	5.8
Gefitinib	7	5.7	5.8
Carboplatin	95	5.7	5.7
Tolvaptan	11	5.6	5.6
Avapritinib	9	5.5	5.5
Docetaxel Anhydrous	47	5.2	5.2
Docetaxel	47	5.2	5.2
Dexamethasone Sodium Phosphate	7	5.1	5.1
Etoposide	50	5.1	5.1
Alpelisib	6	5.1	5.1
Imatinib	12	5.0	5.1
Febuxostat	11	4.9	4.9
Capecitabine	59	4.8	4.9
Pertuzumab	17	4.6	4.6
Everolimus	31	4.5	4.5
Encorafenib	6	4.5	4.5
Prasugrel Hydrochloride	6	4.4	4.4
Granisetron	6	4.2	4.2
Norepinephrine	6	4.2	4.2
Gemcitabine Hydrochloride	29	4.1	4.1
Trastuzumab	37	4.0	4.0
Cladribine	5	3.9	3.9
Erlotinib	5	3.8	3.8
Entecavir	6	3.8	3.8
Pemetrexed	11	3.8	3.8
Panitumumab	8	3.8	3.8
Lanreotide Acetate	4	3.8	3.8
Fosaprepitant Dimeglumine	7	3.8	3.8
Doxorubicin	44	3.7	3.7
Erlotinib Hydrochloride	6	3.6	3.6
Pemetrexed Disodium	18	3.5	3.5
Suvorexant	6	3.4	3.4
Doxorubicin Hydrochloride	15	3.4	3.4
Gemcitabine	18	3.4	3.4
Alteplase	6	3.0	3.0
Palbociclib	31	2.4	2.4
Crizotinib	4	2.3	2.3
Olaparib	6	2.1	2.1

Related reactions

Data source: openFDA FAERS. See the OpenPV methodology and limitations.